Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors

Cancer Research

Volumn 58, Issue 17, 1998, Pages 3909-3917

  Hermans, Ian F ^a   Daish, Angela ^a   Yang, Jianping ^a   Ritchie, David S ^a   Ronchese, Franca ^a  

^a MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOLOGY; CLONAL ANERGY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, NEOPLASM; CARCINOMA, LEWIS LUNG; DENDRITIC CELLS; HEMATOPOIETIC STEM CELLS; IMMUNIZATION; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0032169984     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Bailar, J. C., and Gornik, H. L. Cancer undefeated. N. Engl. J. Med., 336: 1569-1574, 1997.
2. Melief, C. J. M., and Kast, W. M. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol. Rev., 145: 167-177, 1994.
3. Boon, T., Coulie, P. G., and Van den Eynde, B. Tumor antigens recognized by T cells. Immunol. Today, 18: 267-268, 1997.
4. Boon, T., and Van Pel, A. Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line. Proc. Natl. Acad. Sci. USA, 75: 1519-1523, 1978.
5. Ranges, G. E., Figari, I. S., Espevik, T., and Palladino, M. A. Inhibition of cytotoxic T cell development by transforming growth factor β and reversal by recombinant tumor necrosis factor α. J. Exp. Med., 166: 991-998, 1987.
6. Torre-Amione, G., Beauchamp, R. D., Koeppen, H., Park, B. H., Schreiber, H., Moses, H. L., and Rowley, D. A. A highly immunogenic tumor transfected with a murine TGF-β cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. USA, 87: 1468-1490, 1990.
7. Chen, L., Ashe, S., Brady, W. A., Hellstrom, I., Hellstrom, K. E., Ledbetter, J. A., McGowan, P., and Linsley, P. S. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell, 71: 1093-1102, 1992.
8. Townsend, S. E., and Allison, J. P. Tumor rejection after direct Costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (Washington DC), 259: 368-370, 1993.
9. Mueller, D. L., Jenkins, M. K., and Schwanz, R. H. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol., 7: 445-480, 1989.
10. Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., and Levitsky, H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (Washington DC), 264: 961-965, 1994.
11. Bevan, M. J. Antigen presentation to cytotoxic T lymphocytes in vivo. J. Exp. Med., 182: 639-641, 1995.
12. Förster, I., Hirose, R., Arbeit, J. M., Clauser, B. E., and Hanahan, D. Limited capacity for tolerization of CD4+ T cells specific for a pancreatic β cell neo-antigen. Immunity, 2: 573-585, 1995.
13. Moskophidis, D., Lechner, F., Pircher, H., and Zinkemagel, R. M. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature (Lond.), 362: 758-761, 1993.
14. Hermans, I. F., Daish, A., Moroni-Rawson, P., and Ronchese, F. Tumor peptidepulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumor challenge. Cancer Immunol. Immunother., 44: 341-347, 1997.
15. Pircher, H., Buerki, K., Lang, R., Hengartner, H., and Zinkernagel, R. M. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature (Lond.), 342: 559-561, 1989.
16. Finlay, G. J., Ching, L-M., Wilson, W. R., and Baguley, B. C. Resistance of cultured Lewis lung carcinoma cell lines to tiazofurin. J. Natl. Cancer Inst., 79: 291-296, 1987.
17. Metlay, J. P., Witmer Pack, M. D., Agger, R., Crowley, M. T., Lawless, D., and Steinman, R. M. The distinct leukocyte integrins of mouse spleen dendritic cells as identified with new hamster monoclonal antibodies. J. Exp. Med., 171: 1753-1771, 1990.
18. Coligan, J. E., Kruisbeek, A. M., Margulies, D. H., Shevach, E. M., and Strober, W. Current Protocols in Immunology. New York: John Wiley & Sons, 1991.
19. Unkeless, J. C. Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J. Exp. Med., 150: 580-596, 1979.
20. Harris, N., Campbell, C., Le Gros, G., and Ronchese, F. Blockade of CD28/B7 co-stimulation by mCTLA4-Hγl inhibits antigen-induced lung eosinophilia but not Th2 cell development or recruitment in the lung. Eur. J. Immunol., 27: 155-161, 1997.
21. Spitalny, G. L., and Havell, E. A. Monoclonal antibody to murine γ interferon inhibits lymphokine-induced antiviral and macrophage tumoricidal activities. J. Exp. Med., 1/59: 1560-1565, 1984.
22. Cherwinski, H. M., Schumacher, J. H., Brown, K. D., and Mosmann, T. R. Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. J. Exp. Med., 166: 1229-1244, 1987.
23. Fuchs, E. J., and Matzinger, P. Is cancer dangerous to the immune system? Semin. Immunol., 8: 271-280, 1996.
24. Prehn, R. T., and Main, J. M. Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst., 18: 769-778, 1957.
25. Wick, M., Dubey, P., Koeppen, H., Siegel, C. T., Fields, P. E., Chen, L., Bluestone, J. A., and Schreiber, H. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med., 186: 229-238, 1997.
26. Mackay, C. R. Homing of naive, memory and effector lymphocytes. Curr. Opin. Immunol., 5: 423-427, 1993.
27. Ohashi, P. S., Oehen, S., Buerki, K., Pircher, H., Ohashi, C. T., Odermatt, B., Malissen, B., Zinkemagel, R. M., and Hengartner, H. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell, 65: 305-317, 1991.
28. Speiser, D. E., Miranda, R., Zakarian, A., Bachmann, M. F., McKall-Faienza, K., Odermatt, B., Hanahan, D., Zinkemagel, R. M., and Ohashi, P. S. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med., 186: 645-653, 1997.
29. Kurts, C., Heath, W. R., Carbone, F. R., Allison, J., Miller, J. F., and Kosaka, H. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J. Exp. Med., 184: 923-930, 1996.
30. Kurts, C., Kosaka, H., Carbone, F. R., Miller, J. F. A. P., and Heath, W. R. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactivc CD8(+) T cells. J. Exp. Med., 186: 239-245, 1997.
31. Schild, H., Rotzschke, O., Kalbacher, H., and Rammensee, H. G. Limit of T cell tolerance to self proteins by peptide presentation. Science (Washington DC), 247: 1587-1589, 1990.
32. Becker, Y. Anticancer role of dendritic cells (DC) in human and experimental cancers: a review. Anticancer Res., 12: 511-520, 1992.
33. Guerder, S., and Matzinger, P. A fail-safe mechanism for maintaining self-tolerance. J. Exp. Med., 176: 553-564, 1992.
34. Kirberg, J., Bruno, L., and von Boehmer, H. CD4+8-help prevents rapid deletion of CD8+ cells after a transient response to antigen. Eur. J. Immunol., 23: 1963-1967, 1993.
35. Cella, M., Scheidegger, D., Palmerlehmann, K., Lane, P., Lanzavecchia, A., and Alber, G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity-T-T help via APC activation. J. Exp. Med., 184: 747-752, 1996.